Ground News

News from immixbio.com

See all of immixbio.com news coverage in one place. Discover how immixbio.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 5 headlines reported on by immixbio.com during the past 3 months.

We’ve assigned a media bias rating of unknown to immixbio.com. You can read more about our methodology here.

If you want to know if immixbio.com is credible or reliable, look no further. We rank immixbio.com as Unknown factuality. Find out more about our methodology here.

Information about immixbio.com

Where is immixbio.com located?immixbio.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top immixbio.com News

Innovation · Washington

Immix Biopharma Attends FDA CEO Forum in Washington DC

100% Center coverage: 1 sources

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –See the Story

$NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis$

Maryland · Maryland

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.See the Story

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - IMMIX BIOPHARMA INC

– Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET – – Attend the event here: https://lifescievents.com/event/immix-asco – LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event to discuss inter…Maryland · Maryland Read Article

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - IMMIX BIOPHARMA INC

– Oral presentation Tuesday, June 3, 2025 in Chicago – LOS ANGELES, April 23, 2025 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the u…Chicago, IL · Chicago Read Article

You've scrolled to the bottom of the feed, there are no more stories.